392 related articles for article (PubMed ID: 25048716)
1. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.
Rehermann B; Bertoletti A
Hepatology; 2015 Feb; 61(2):712-21. PubMed ID: 25048716
[TBL] [Abstract][Full Text] [Related]
2. Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.
Kondo Y; Ueno Y; Ninomiya M; Tamai K; Tanaka Y; Inoue J; Kakazu E; Kobayashi K; Kimura O; Miura M; Yamamoto T; Kobayashi T; Igarashi T; Shimosegawa T
J Gastroenterol; 2012 Dec; 47(12):1323-35. PubMed ID: 22588246
[TBL] [Abstract][Full Text] [Related]
3. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
4. Effect of IL28B genotype on hepatitis B and C virus infection.
Stättermayer AF; Ferenci P
Curr Opin Virol; 2015 Oct; 14():50-5. PubMed ID: 26284971
[TBL] [Abstract][Full Text] [Related]
5. Alpha-interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses.
Guptan RC; Thakur V; Raina V; Sarin SK
J Gastroenterol Hepatol; 1999 Sep; 14(9):893-8. PubMed ID: 10535471
[TBL] [Abstract][Full Text] [Related]
6. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection.
Liu CJ; Chen PJ
World J Gastroenterol; 2014 Mar; 20(11):2955-61. PubMed ID: 24659886
[TBL] [Abstract][Full Text] [Related]
7. Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus.
Pagliaccetti NE; Robek MD
J Interferon Cytokine Res; 2010 Aug; 30(8):585-90. PubMed ID: 20645875
[TBL] [Abstract][Full Text] [Related]
8. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
[TBL] [Abstract][Full Text] [Related]
9. Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses.
Agrawal B; Kumar R
World J Gastroenterol; 2016 Jul; 22(25):5623-6. PubMed ID: 27433078
[TBL] [Abstract][Full Text] [Related]
10. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C.
Uyanikoglu A; Akyuz F; Baran B; Simsek BP; Ermis F; Demir K; Gulluoglu M; Badur S; Kaymakoglu S
Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):485-90. PubMed ID: 23665172
[TBL] [Abstract][Full Text] [Related]
11. Management of psoriasis patients with hepatitis B or hepatitis C virus infection.
Bonifati C; Lora V; Graceffa D; Nosotti L
World J Gastroenterol; 2016 Jul; 22(28):6444-55. PubMed ID: 27605880
[TBL] [Abstract][Full Text] [Related]
12. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
Potthoff A; Deterding K; Trautwein C; Rifai K; Manns MP; Wedemeyer H
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):906-9. PubMed ID: 17873617
[TBL] [Abstract][Full Text] [Related]
13. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
[TBL] [Abstract][Full Text] [Related]
14. Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model.
Wu J; Huang S; Zhao X; Chen M; Lin Y; Xia Y; Sun C; Yang X; Wang J; Guo Y; Song J; Zhang E; Wang B; Zheng X; Schlaak JF; Lu M; Yang D
J Virol; 2014 Sep; 88(18):10421-31. PubMed ID: 24920792
[TBL] [Abstract][Full Text] [Related]
15. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin.
Yalcin K; Degertekin H; Yildiz F; Kilinc N
J Gastroenterol; 2003; 38(8):796-800. PubMed ID: 14505137
[TBL] [Abstract][Full Text] [Related]
16. Genetic Polymorphisms within Interferon-λ Region and Interferon-λ3 in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses.
Grzegorzewska AE
Curr Med Chem; 2019; 26(25):4832-4851. PubMed ID: 30027841
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children.
Indolfi G; Azzari C; Resti M
World J Gastroenterol; 2014 Jul; 20(28):9245-52. PubMed ID: 25071317
[TBL] [Abstract][Full Text] [Related]
19. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
Gluhovschi C; Gadalean F; Kaycsa A; Curescu M; Sporea I; Gluhovschi G; Petrica L; Velciov S; Bozdog G; Bob F; Vernic C; Cioca D
Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):744-50. PubMed ID: 21320001
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection.
Hou J; van Oord G; Groothuismink ZM; Claassen MA; Kreefft K; Zaaraoui-Boutahar F; van IJcken WF; Osterhaus AD; Janssen HL; Andeweg AC; de Knegt RJ; Boonstra A
J Virol; 2014 Nov; 88(21):12254-64. PubMed ID: 25100847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
